In a recent revaluation, UK-based AstraZeneca has admitted for the first time in court that its Covid vaccine can lead to a rare blood clotting condition. This was a crucial moment in a class action lawsuit brought by families who allege harm caused by the pharmaceutical giants vaccine. The admission comes amidst legal proceedings triggered by claims of serious health complications, including deaths, allegedly caused by the vaccine. Lawyers representing dozens of claimants assert that some cases could result in compensation payouts totaling up to 20 million pounds.BOMBSHELL NEWSAstraZeneca just ADMITTED IN COURT that their covid injection can cause a severe blood clot side effect.This is absolutely huge news.They are now being sued in a class action lawsuit from victims that have suffered after being lied to by the experts about… pic.twitter.com/4CcISuihLA— PeterSweden (@PeterSweden7) April 29, 2024Rare blood clotting conditionAstraZeneca acknowledged in a legal document that its vaccine can cause thrombosis with thrombocytopenia syndrome (TTS), characterized by blood clot formation alongside low platelet levels crucial for clotting. This condition was previously known as vaccine-induced immune thrombotic thrombocytopenia (VITT).Previous side effects of AstraZenecaThis exceedingly rare complication has been listed as a potential side effect of the jab. AstraZenecas admission may lead to individual settlements for those impacted by this adverse reaction.Legal stance and implicationsThe admission represents a major shift from previous denials and places potential compensation responsibility on UK taxpayers. This is due to an indemnity deal AstraZeneca had with the government during the pandemic peak, aimed at expediting vaccine production while protecting the pharmaceutical company from legal liability.Despite legal challenges, AstraZeneca gained financial success, with revenues exceeding 10 billion pounds in the first quarter of 2024. While expressing sympathy for affected individuals, the company reaffirmed its commitment to safety standards and emphasized regulatory authorities stringent safety measures.Less than a year after its initial approval, AstraZenecas Covid-19 vaccine was distributed to 170 countries worldwide in two billion doses.
